Table 1 Baseline characteristics of the study population

Age (years)

68.8 ± 10.7

68.8 ± 10.7

68.5 ± 10.6

0.701

Male sex

1453 (56.6%)

1323 (56.5%)

130 (57.0%)

0.889

Medical history

 Hypertension

1862 (72.5%)

1710 (73.1%)

152 (66.7%)

0.039

 Diabetes

690 (26.9%)

637 (27.2%)

53 (23.2%)

0.196

 CAD/previous MI

416 (16.2%)

378 (16.2%)

38 (16.7%)

0.841

 Peripheral arterial disease

32 (1.2%)

31 (1.3%)

1 (0.4%)

0.357

 Congestive heart failure

702 (27.3%)

660 (28.2%)

42 (18.4%)

0.002

 Previous ischemic stroke/TIA

538 (21.0%)

502 (21.5%)

36 (15.8%)

0.045

 Pulmonary disease

24 (0.9%)

24 (1.0%)

0 (0.0%)

0.265

 Hepatic disease

24 (0.9%)

23 (1.0%)

1 (0.4%)

0.717

 Renal disease

1392 (54.2%)

1287 (55.0%)

105 (46.1%)

0.010

CHA₂DS₂-VASc score

3.3 ± 1.6

3.3 ± 1.6

3.0 ± 1.6

0.001

HAS-BLED score

1.6 ± 1.0

1.6 ± 1.0

1.1 ± 0.8

 < 0.001

SAMe-TT₂R₂ score

3.1 ± 0.8

3.1 ± 0.8

3.1 ± 0.9

0.685

 SAMe-TT₂R₂ score 0–2

617 (24.0%)

558 (23.8%)

59 (25.9%)

0.493

Components of SAMe-TT₂R₂ score

 Female sex

1115 (43.4%)

1017 (43.5%)

98 (43.0%)

0.889

 Age < 60 years

491 (19.1%)

443 (18.9%)

48 (21.1%)

0.437

 Medical history > 2 comorbidities

957 (37.3%)

893 (38.2%)

64 (28.1%)

0.003

 Interacting drug treatment

132 (5.1%)

107 (4.6%)

25 (11.0%)

 < 0.001

 Tobacco use within 2 years

59 (2.3%)

54 (2.3%)

5 (2.2%)

0.912

 Non-Caucasian race

–

–

–

–

Serum creatinine (mg/dL)

1.3 ± 2.5

1.3 ± 2.7

1.1 ± 0.3

0.235

LVEF (%)

59.7 ± 14.0

59.5 ± 14.2

61.3 ± 12.6

0.043

TTR (%)

52.1 ± 27.4

52.1 ± 27.4

–

–

 TTR < 65%

1494 (65.1%)

1494 (65.1%)

–

–

 TTR 65 to < 70%

168 (7.3%)

168 (7.3%)

–

–

 TTR ≥ 70%

633 (27.6%)

633 (27.6%)

–

–

Antithrombotic medications

Antiplatelet

309 (12.0%)

294 (12.6%)

15 (6.6%)

0.008

 Aspirin

264 (10.3%)

252 (10.8%)

12 (5.3%)

0.009

 P2Y₁₂ inhibitors

81 (3.2%)

77 (3.3%)

4 (1.8%)

0.205